TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T
cells expressing a single-domain antibody that recognizes human CD19, fused to the
CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell
receptor (TCR) complex.
This is a Phase 1/2 open-label study to evaluate the safety of autologous genetically
engineered TC-110 T cells in patients with aggressive NHL (DLBCL, PMBCL, TFL), high-risk
indolent NHL (including MCL), or adult ALL.